Worried about the impact of GLP-1 shortages on your employees? Calibrate has shown that medication is a tool—not the entire treatment. Our comprehensive lifestyle intervention empowers members to achieve sustainable weight loss—with or without continuous medication, and we have the data to back it up. Calibrate recently conducted a real-world analysis of medication access and clinical outcomes for obesity treatment with GLP-1s. This analysis, presented at the Endocrine Society, reveals that even with significant gaps in medication access, Calibrate members achieved clinically significant weight loss outcomes. Key Findings: - Members who did not experience a 13-week medication disruption over 24 months achieved an average weight loss of 17.28% at their 12-month mark. - Members who experienced a medication disruption of at least 13 weeks over the same period still saw an impressive average weight loss of 14.96% Whether on a GLP-1 or not, Calibrate members lose weight—and keep it off, for good. To read more about our findings, check out our poster: https://lnkd.in/eC_wHCCW #HolisticApproach #GLP1s #ClinicalOutcomes
Calibrate’s Post
More Relevant Posts
-
Author of "ChatGPT, MD" | Forbes Healthcare Contributor | Stanford Faculty | Podcast Host | Former CEO of Permanente Medical Group (Kaiser Permanente)
Last month, I published an article in my newsletter "Breaking the Healthcare Rules" about Ozempic as a weight-loss drug. As expected, the article drew lots of interest and sparked significant conversation here on LinkedIn. While GLP-1 medications have the potential to help our nation fight obesity, they carry an oversized price tag: upwards of $16,000 per year. With that in mind, I’d like to ask for your thoughts on obesity in America. My new poll contains three multiple-choice questions and takes most users less than 2 minutes to complete. Responses are confidential and cumulative totals will be shared next month. For results of last month's poll, check out the comments. #healthcare #healthcareonlinkedin #opinionpoll
To view or add a comment, sign in
-
Medical weight loss refers to a structured weight management program that is supervised by medical professionals, typically including physicians and other healthcare providers. It focuses on achieving weight loss and improving overall health through evidence-based strategies and interventions. These programs are tailored to individual needs and often involve a comprehensive approach that combines diet, physical activity, behavior modification, and medication or other medical interventions. They are designed to address underlying factors contributing to weight gain or difficulty losing weight, such as hormonal imbalances, metabolic disorders, or certain medical conditions. https://lnkd.in/eqiesDdB #ApexHormoneHealth #HormoneReplacement #TestosteroneReplacement
To view or add a comment, sign in
-
-
⚖️Understanding weight loss with weight loss medications! 💊When people suffering from #obesity use a medicine called tirzepatide, they can lose a lot of weight, but e new study shows something important for these people! Those who kept taking tirzepatide for more than a year continued to lose weight, but, those who stopped taking it and switched to a fake pill (placebo) started to gain weight back again! 🔬For the professionals out there: Among adults with obesity who had previously lost weight (21 percent mean weight reduction) during a 36-week, open-label trial of tirzepatide, those randomly assigned to continue tirzepatide for 52 weeks experienced additional weight loss, whereas those assigned to placebo partially regained (-5.5 versus +14 percent mean weight change, respectively) 🚨This study tells us that to keep weight off with drugs, it might be necessary to takethem for a long time, which is something unsustainable and not so economic and healthy probably! 📖Read original study: https://lnkd.in/eYrSU58j #WeightLoss #Tirzepatide #StayHealthy
To view or add a comment, sign in
-
-
ECFMG Certified| Admin of Amedcure | Medical Officer | Primary Care Physician | Proficient in AI, Microsoft Office, SPSS, R, Notion, Canva, Graphics, Video Editing, Python and Web Development
Excited to explore the intricate details of weight management goals in pharmacological therapy for individuals with diabetes! These goals are vital for achieving lasting weight loss, enhancing insulin sensitivity, and improving overall health. Choosing the right pharmacological agent in clinical settings demands a patient-centered approach, taking into account factors like comorbidities, medication history, and patient preferences. Eager to apply these insights to enhance diabetes management outcomes! #DiabetesManagement #WeightLossGoals #PatientCenteredCare
To view or add a comment, sign in
-
-
Active B12 Test Market size was valued at USD 182.23 Mn. in 2023 and the Active B12 Test revenue is expected to grow at a CAGR of 24.7% from 2024 to 2030, reaching nearly USD 854.45 Mn. by 2030. The Active B12 Test Market is witnessing remarkable growth as awareness of the importance of vitamin B12 in overall health rises. Active B12 tests offer accurate detection of B12 deficiency, which is crucial for preventing serious health issues such as anemia, neuropathy, and cognitive impairments. With advancements in diagnostic technology, healthcare providers can now offer more precise and timely interventions. Stay informed about the latest trends and innovations in this vital sector. Request for sample Request:https://lnkd.in/d9nsWJkA #ActiveB12Test #HealthcareInnovation #DiagnosticTesting #VitaminB12 #HealthAndWellness #MedicalAdvancements
To view or add a comment, sign in
-
-
Some of the largest organizations in the US spend upwards of $16,000 per person per year on costs associated with GLP-1s. Can your organization afford to spend that much on GLP-1s? Leaders are in a tricky position here. Obesity is a costly chronic condition that impacts around 40% of Americans. Getting ahead of it can prevent rising cardiometabolic conditions like diabetes and the growing cost to treat them. Unfortunately, many of these "miracle" treatments contribute to the exorbitant cost. How can you offer the right care at the right time for your people, knowing there aren't unlimited funds to cover the increasing demand for these medications? Join our expert panel on August 24th, 2023 for a webinar, The GLP-1 Cost Crisis: What Can You Do? You'll learn: — What obesity step therapy is and how it can dramatically reduce GLP-1 costs — How GLP-1 and other anti-obesity medications can be properly managed without costly lifetime prescriptions — Why step therapy helps organizations sustain and scale clinical and engagement outcomes #obesity #employeehealth #GLP1
Register for the webinar here!
vida.zoom.us
To view or add a comment, sign in
-
**Do I stop taking anti-obesity medication once I reach my goal weight?** My name is Dr. Nikita Shah, and I’m an obesity medicine physician in Orlando, FL No, we do not stop taking anti-obesity medication once goal weight is reached. Semaglutide (GLP1A aka Ozempic or Wegovy) or Tirzepatitde (GLP1A/GIP aka Mounjaro or Zepbound) and other antiobesity medications (eg: Contrave, Qsymia) are studied and designed to be taken long term, like any other medication for chronic conditions just like diabetes, hypertension, and hypothyroidism. Obesity is a chronic, relapsing medical condition. This means that if we stop treatment, we are prone to weight regain. AOM is a great tool to maintain during the weight maintenance phase of weight care. Also, the good news is that with the treatment of obesity using medication + lifestyle changes, we can successfully improve a person’s quality of life and health outcomes.😊 To learn more visit: weight-sense.com #weightlossjourney #weightlossmotivation #antiobesitymedication #weightsense
To view or add a comment, sign in
-
-
When it comes to managing patients living with obesity, we’ve made no secret of our belief that a holistic approach is the best option. And we’ve got the data to prove it. In a 90-day evaluation, patients using GLP-1s who took advantage of the Numan app and our personalised behavioural coaching were associated with 36% more weight loss compared to those just taking the medication. GLP-1 medications have the potential to help people on their weight loss journeys – but when they make behavioural changes alongside these medicines, the combined results are significant. Our app gives patients the tools they need to make changes, set goals and easily track their progress. Patients can also access behavioural coaching from behaviour change experts, nutritionists and exercise physiologists, who offer tailored advice on how to hit their target. #health #weightloss #medicine #healthcoaching #obesity
To view or add a comment, sign in
-
Please join our CMO and Head of Cardiometabolic Care on Aug 24th at 1 PM ET for a webinar addressing the GLP-1 tsunami. Learn more about the importance of an evidence-based obesity step therapy program that is deeply personalized to the individual and incorporates cognitive behavioral therapy, medical nutritional therapy and culturally adapted meal planning. Dr. Frank and Gretchen will also cover the economics of a properly managed step therapy program including : 1. What obesity step therapy is and how it can dramatically reduce GLP-1 costs 2. How GLP-1 and other anti-obesity medications can be properly managed without costly lifetime prescriptions 3. Why step therapy helps organizations sustain and scale clinical and engagement outcomes
Some of the largest organizations in the US spend upwards of $16,000 per person per year on costs associated with GLP-1s. Can your organization afford to spend that much on GLP-1s? Leaders are in a tricky position here. Obesity is a costly chronic condition that impacts around 40% of Americans. Getting ahead of it can prevent rising cardiometabolic conditions like diabetes and the growing cost to treat them. Unfortunately, many of these "miracle" treatments contribute to the exorbitant cost. How can you offer the right care at the right time for your people, knowing there aren't unlimited funds to cover the increasing demand for these medications? Join our expert panel on August 24th, 2023 for a webinar, The GLP-1 Cost Crisis: What Can You Do? You'll learn: — What obesity step therapy is and how it can dramatically reduce GLP-1 costs — How GLP-1 and other anti-obesity medications can be properly managed without costly lifetime prescriptions — Why step therapy helps organizations sustain and scale clinical and engagement outcomes #obesity #employeehealth #GLP1
Register for the webinar here!
vida.zoom.us
To view or add a comment, sign in